Programs Targeting a Range of Unmet Needs in CNS

Minerva Neurosciences is focused on central nervous system (CNS) diseases. Our programs target the treatment of negative symptoms of schizophrenia and Parkinson’s disease, each of which affects millions of people around the world.

According to Datamonitor, an independent market research firm, in 2020 approximately 2.9 million people suffered from schizophrenia and 2.1 million suffered from Parkinson’s disease in the United States, Japan and the five major European Union markets of France, Germany, Italy, Spain and the United Kingdom.

Currently available treatment options for these conditions are known to have significant limitations that often result in high rates of discontinuation of therapy and unsatisfactory efficacy and safety profiles. Patients, physicians and family members also face significant challenges associated with the burden of these and many other CNS diseases.

We are pursuing the development of new therapeutic options based on our deep knowledge of the pathology of CNS diseases, the pharmacology of our compounds and our understanding of desired outcomes for unmet patient needs.

Minerva’s Programs

Our potentially first-in-class product candidates include: Roluperidone (MIN-101) and MIN-301.

Status as of March 2021